Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2024

Lo Y, Lester SC, Ellis IO, Lanjewar S, Laurini J, Patel A, et al. Identification of Glandular (Acinar)/Tubule Formation in Invasive Carcinoma of the Breast: A Study to Determine Concordance Using the World Health Organization Definition. Arch Pathol Lab Med. 2024;148(10):1119-1125.

Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GN, Pannellini T, et al. Distinct mesenchymal cell states mediate prostate cancer progression. Nat Commun. 2024;15(1):363.

Chen Y, Zhang L, Shi X, Han J, Chen J, Zhang X, et al. Characterization of the Nucleus Pulposus Progenitor Cells via Spatial Transcriptomics. Adv Sci (Weinh). 2024:e2303752.

Kudman S, Semaan A, Assaad MA, Gogineni S, M Martin L, Mathew S, et al. Optimization of Fluorescence In Situ Hybridization Protocols in the Era of Precision Medicine. Curr Protoc. 2024;4(6):e1093.

Li J, Chin CR, Ying H-, Meydan C, Teater MR, Xia M, et al. Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment. Nat Commun. 2024;15(1):2879.

Kubiak JM, Klevay M, Hilt EE, Ferrieri P. Acute Meningoencephalitis Associated with Borrelia miyamotoi, Minnesota, USA. Emerg Infect Dis. 2024;30(7):1472-1474.

Lee-Saxton YJ, Egan CE, Bratton BA, Thiesmeyer JW, Greenberg JA, Marshall TE, et al. Low Mitotic Activity in Papillary Thyroid Cancer: A Marker for Aggressive Features and Recurrence. J Clin Endocrinol Metab. 2024.

Li Y, Deng K, Kaner J, Geyer JT, Ouseph M, Fang F, et al. Detection of Hybrid Fusion Transcripts, Aberrant Transcript Expression, and Specific Single Nucleotide Variants in Acute Leukemia and Myeloid Disorders with Recurrent Gene Rearrangements. Pathobiology. 2024;91(1):76-88.

Adeuyan O, Magro CM, Trager MH, Gordon ER, Lapolla BA, Schreidah CM, et al. Plasma cell and neutrophil enriched neovascularization with granulomatous lymphangitis in POEMS syndrome. JAAD Case Rep. 2024;49:125-128.

Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, et al. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer Lett. 2024;584:216608.